THE ROLE OF RADIOTHERAPY DELAY IN THE CHEMORADIATION TREATMENT FOR STAGE III INOPERABLE NON-SMALL CELL LUNG CANCER
Abstract
Introduction. One third of non-small cell lung cancer (NSCLC) patients have locally advanced inoperable Stage III tumors. Increasing number of induction chemotherapy (iCT) cycles may lead to delay of the start of radiotherapy (RT) and decrease survival. Objective. To evaluate a clinical impact of the starting time of RT among Stage III NSCLC patients after iCT on overall survival (OS). Materials and methods. The OS was calculated in patients, receiving radical RT during or later than 150 days after starting of iCT (RT150). Kaplan-Meier method with log-rank for intergroup comparisons was used. Correction for initial factors was made using Cox regression. Results. Overall, 49 patients with stage III NSCLC who received RT after iCT were selected. Twenty-five patients were irradiated during the period less then 150 days after the start of iCT, while other 24 – in more than 150 days. At distribution analysis, in the group RT>150 was higher proportion of patients with T4 (p=0.029) and with B stage (P=0.003), the other initial factors were distributed uniformly. The median (Me) OS was 19.9 (95 % confidence interval (CI) 16.8-23.2) and 21,0 (95 % CI 14.9-27.2) months, c2=0,017, p=0.895 in groups RT>150 and RT≤150, respectively. Me OS was 22.5 (95 % CI 10,2-34.9), 18.9 (95 % CI 16.9-20.9), and 18.4 (95 % CI 15.4-21.4) months, c2=4,42, P=0.110 for patients receiving 2, 3-4, 5 or more courses of induction CT, respectively. Hazard ratio (HR) of death in patients with a longer interval before the end of RT was 1.041 (95 % CI 0,571-1,897) and 1.485 (95 % CI 0,691-3,189) in univariate and multivariate analysis, respectively. Conclusion. In a retrospective analysis the delay of RT start after iCT leads to non-significant decrease of survival. More than two courses of iCT are not appropriate. The results need to be confirmed in a prospective randomized trial.
About the Authors
E. P. Solov’eva
Arkhangelsk clinical Oncological Dispensary;
Northern State Medical University, Arkhangelsk
Russian Federation
Russian Federation
Solovyeva Ekaterina Petrovna, graduate student of the Diagnosis, Radiotherapy and Clinical Oncology Department, Northern State Medical University; oncologist, Chemotherapy Department, Arkhangelsk Clinical Cancer Center.
Phone: +7 921 719-53-71. E-mail: solovyeva_ek@mail.ru. SPIN-code: 8782-6836
S. M. Asakhin
Arkhangelsk clinical Oncological Dispensary;
Northern State Medical University, Arkhangelsk
Russian Federation
Russian Federation
Asakhin Sergey Mikhailovich, MD, PhD, assistant professor, Department of Diagnosis, Radiation Therapy and Clinical Oncology, Northern State Medical University (Arkhangelsk).
Phone: +7 921 244-22-70. E-mail: asakin@atknet.ru. SPINcode: 10704-9613
M. Ju. Val’kov
Arkhangelsk clinical Oncological Dispensary;
Northern State Medical University, Arkhangelsk
Russian Federation
Russian Federation
Valkov Mikhail Yuryevich, MD, DSc, Professor, Head of the Department of Diagnosis, Radiation Therapy and Clinical Oncology, Northern State Medical University(Arkhangelsk).
Phone: +7 911 554-57-95. E-mail: m_valkov@mail.ru. SPINcode: 8608-8239
References
1. Valkov M.Yu., Skripchak Yu.V., Solovyova E.P., Valkov A.Yu, Asakhin S.M. Methods of treatment and outcomes in locally advanced Stage III lung cancer: population-based study // Vestnik RNCRR. 2012. Vol. 3. №: 12. P. 7–14. URL: http://vestnik.rncrr.ru/vestnik/v14/papers/valkov_v14.htm (24.01.2015). [in Russian]
2. Garin A.M, Bazin I.S. Reference manual for drug therapy of solid tumors. M., 2007. 300 p. [in Russian]
3. Kaprin A.D., Starinskij V.V., Petrova G.V. Cancer incidence in Russia in 2013 (morbidity and mortality) // M., 2015. P. 250. [in Russian]
4. Guidelines for chemotherapy of malignant tumors // Ed. N.I. Perevodchikova. M., 2005. 704 p. [in Russian]
5. Solovyova E.P., Kononova G.V., Valkov M.Yu. Choice of method sequence for conservative treatment for Stage III inoperable non-small cell lung cancer: retrospective survival analysis // Vestnik RNCRR. 2012. Vol. 3. № 12. P. 7. URL: http://vestnik.rncrr.ru/vestnik/v12/papers/solo_v12.htm (18.01.15). [in Russian]
6. Solovyova E.P., Asakhin S.M., Valkov M.Yu. The clinical significance of the delay start special treatment in patients with unresectable NSCLC stage III: the results of our research and literature review // Sibirskiy onkologicheskiy zhurnal. 2014. № 3. P. 11–18. [in Russian]
7. TNM: Classification of malignant tumors. 6th edition. SPb., 2003. 243 p. [in Russian]
8. Chissov V.I., Starinskiy V.V., Petrova G.V. State of cancer care in Russia in 2009. M. , 2010. 196 p. [in Russian]
9. Alberg A.J., Brock M.W., Samet J.M. Epidemiology of lung cancer: looking to the future // J. Clin. Oncol. 2005. Vol. 23. Р. 3175–3185.
10. Bonner J.A., McGinnis W.L., Stella P.J., Marschke Jr.F., Sloan J.A., Shaw E.G., Mailliard J.A., Creagan E.T., Ahuja R.K., Johnson P.A. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study // Cancer. 1998. Vol. 82. P. 1037–1048.
11. Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. // U.S. Department of Health and Human Services. National Cancer Institute. 2006. P. 71.
12. De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., Minken A., Wanders R., Lutgens L., Hochstenbag M., Boersma L., Wouters B., Lammering G., Vansteenkiste J., Lambin P. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer // J. Clin. Oncol. 2006. Vol. 24. P. 1057–1063.
13. El Sharouni S.Y., Kal H.B., Battermann J.J. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy // Br. J. Cancer. 2003. Vol. 89. P. 2184–2189.
14. Filderman A.E., Shaw C., Matthay R.A. Lung cancer. Part I: etiology, pathology, natural history, manifestations, and diagnostic techniques // Invest. Radiol. 1986. Vol. 211. P. 80–90.
15. Fujimura S., Suda S., Yamauchi A. [et al.]. Tumor doubling time and PPD skin test reactivity in resectable lung cancer // J. Jpn. Lung Cancer Soc. 1979. Vol. 19. P. 135–142.
16. Geddes D.M. The natural history of lung cancer: a review based on rates of tumour growth // Br. J. Dis. Chest. 1979. Vol. 73. P. 1–17.
17. Jeremic B., Koning C. Induction Chemotherapy Before Chemoradiation in Locally Advanced Non–Small-Cell Lung Cancer: Failure After Failure, Again and Again // J. Clin. Oncol. 2008. Vol. 26. P. e1-e2.
18. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012 // CA Cancer J Clin. 2012. Vol. 62. P. 10–29. URL: http://onlinelibrary.wiley.com/doi/10.3322/caac.20138/pdf (дата обращения: 10.01.2015).
19. Tannock I.F. Combined modality treatment with radiotherapy and chemotherapy // Radiother Oncol. 1989. Vol. 16. P. 83–101.
20. Usuda K., Saito Y., Sagawa M., Sato M., Kanma K., Takahashi S., Endo C., Chen Y., Sakurada A., Fijimura S. Tumor doubling time and prognostic assessment of patients with primary lung cancer // Cancer. 1994. Vol. 74. P. 2239–2244.
Review
For citations:
Solov’eva E.P., Asakhin S.M., Val’kov M.J. THE ROLE OF RADIOTHERAPY DELAY IN THE CHEMORADIATION TREATMENT FOR STAGE III INOPERABLE NON-SMALL CELL LUNG CANCER. Siberian journal of oncology. 2015;1(4):27-33. (In Russ.)
Views:
1019
Email this article 
